Related references
Note: Only part of the references are listed.EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Mai He et al.
CLINICAL CANCER RESEARCH (2012)
Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2012)
Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
Fausto Petrelli et al.
CLINICAL LUNG CANCER (2012)
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
N. Girard et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Tumour molecular profiling for deciding therapy-the French initiative
Frederique Nowak et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study
Ramon Andrade de Mello et al.
TUMOR BIOLOGY (2012)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project-Part 1)
Michele Beau-Faller et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Screening for EGFR mutations in lung cancer, a report from India
Rashmita Sahoo et al.
LUNG CANCER (2011)
What is the best sequence of treatment for patients with EGFR mutations?
B. Besse et al.
REVUE DE PNEUMOLOGIE CLINIQUE (2011)
A simple view on lung cancer biology: The EGFR pathway
A-M Ruppert et al.
REVUE DES MALADIES RESPIRATOIRES (2011)
Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Issa J. Dahabreh et al.
CLINICAL CANCER RESEARCH (2010)
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Robert Pirker et al.
Journal of Thoracic Oncology (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods
D. Talaulikar et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Epidermal growth factor independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
JR Jiang et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
W Pao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
